AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05447143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time up and go- 25 steps walking test
Description: Evaluation for walking
Study NCT05447143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Time up and go- 25 steps walking test
Description: Evaluation for walking
Study NCT05447143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Quality of Life
Description: Evaluation of quality of life
Study NCT05447143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multiple Sclerosis Quality of Life
Description: Evaluation of quality of life
Study NCT05447143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief International Cognitive Assessment for MS (BICAMS)
Description: Evaluation of cognitive functions
Study NCT05447143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brief International Cognitive Assessment for MS (BICAMS)
Description: Evaluation of cognitive functions
Study NCT05447143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beck Depression and Anxiety Scale
Description: Evaluation of depression and anxiety
Study NCT05447143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Beck Depression and Anxiety Scale
Description: Evaluation of depression and anxiety
Study NCT06477744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic embryonic stem cellderived A9 dopamine progenitor cell (A9-DPC)_Low Dose
Description: 1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC~   -Low Dose : 7.0X10\^6 cells (Use 3.15X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3℃)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side.
Study NCT06477744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic embryonic stem cellderived A9 dopamine progenitor cell (A9-DPC)_High Dose
Description: 1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC~   -High Dose : 1.4X10\^7 cells (Use 6.30X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3℃)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side.
Study NCT05488769 — intervention group
Intervention type: DEVICE
Intervention: Clareon Vivity extended depth of focus (EDOF) intraocular lens
Description: Implantation with the Clareon Vivity extended depth of focus (EDOF) intraocular lens
Study NCT05287490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FormaV and VTone
Description: Eligible subjects will receive 3 treatments(every 2 weeks) with the FormaV and VTone Applicators according to the study protocol.
Study NCT03175887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression.
Study NCT03175887 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TMS
Description: Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression.
Study NCT05133323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG09222
Description: Lu AG09222 will be administered per schedule specified in the arm.
Study NCT05133323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to Lu AG09222 will be administered per schedule specified in the arm.
Study NCT05407285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabis 0 mg, placebo
Description: Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
Study NCT05407285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis 20 mg,
Description: Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
Study NCT05407285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis 50 mg
Description: Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
Study NCT05407285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis 100 mg
Description: Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
Study NCT05407285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis 200 mg
Description: Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
Study NCT05619666 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Acute rehabilitation program
Description: Patients included in the study started the rehabilitation program when they were hemodynamic stable, when it was determined that it was safe for patients. Until discharge from the hospital, a re-evaluation of neuromuscular and respiratory function was performed.
Study NCT04797507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210 plus Anlotinib
Description: SHR-1210: a novel anti-PD-1 antibody Anlotinib: a multi-kinase inhibitor
Study NCT05010213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Educational intervention
Study NCT05293522 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NTX-001
Description: 2 solutions plus a delivery device; one time use surgical product
Study NCT05822739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBM-P002
Description: Genetic: single- dose intracranial injection of BBM-P002 Neurosurgical delivery of BBM-P002 to the brain
Study NCT05369559 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Mini bolus 50
Description: receiving a mini-bolus A:50 ml of crystalloid solution, regularly infused over 30 seconds
Study NCT05597995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Tetradecyl Sulfate
Description: subjects epidermoid cysts will be treated with 1.5% sodium tetradecyl sulfate foam
Study NCT04797208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-Time CGM
Description: Participants will be wearing a real-time continuous glucose sensor which will enable their glucose levels to be remotely monitored. High and Low glucose alerts will also be available.
Study NCT04797208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capillary blood glucose testing with masked CGM
Description: Participants will have their glucose monitored in hospital in the conventional manner using the NovaStat® glucometer or similar CE-marked glucose meter) and insulin dose adjusted by the treating clinical team as per usual hospital guidelines. A masked subcutaneous CGM will be inserted for data collection only.
Study NCT04995068 — intervention group
Intervention type: RADIATION
Intervention: Head CT to determine presence of traumatic intracranial lesion
Description: Head CT to determine presence of traumatic intracranial lesion
Study NCT06418113 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated stereotactic radiotherapy
Description: conformal hypofractionated stereotactic radiotherapy to the FLAIR hyperintense signal, including the contrast-enhancing tumor on T1, with a total dose of 3990 cGy at the margin in 15 fractions of 266 cGy, one session per day, five days a week, and concurrent temozolomide (TMZ) at 75 mg/m2/day for 7 days/week during the irradiation period
Study NCT06418113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic biopsy
Description: Stereotactic biopsy
Study NCT05369559 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: passive leg rising test
Description: Passive leg raising technique: Initially, the patient is placed semi-recumbent with the head of the bed at 45°. After recording baseline measurement, the head of the bed is lowered and the legs are elevated to 45° for 2 minutes
Study NCT04860362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS
Description: Structured social skills curriculum including didactics, behavioral rehearsal, parent coaching, and parent coaching support.
Study NCT04860362 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PEERS
Description: Structured social skills curriculum including didactics, behavioral rehearsal, parent coaching, and parent coaching support.
Study NCT05331690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac Ophthalmic
Description: Topical nepafenac (Nevanac) 3 mg/ml starter the day before surgery
Study NCT05331690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac Ophthalmic
Description: Topical nepafenac (Nevanac) 3 mg/ml started the day after surgery
Study NCT05331690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Ophthalmic
Description: Topical dexamethasone 1 mg/ml (Spersadex) started the day after surgery
Study NCT05518305 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Medical Imaging
Description: magnetic resonance imaging
Study NCT00956176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir
Description: Single dose of 5 mg/kg administered in 100 ml of normal saline solution through a foley catheter to bladder. The catheter will be clamped for 2 hours to keep the drug in bladder.
Study NCT04995029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transmucosal Buprenorphine
Description: Transmucosal (TM) buprenorphine as selected by the Investigator per local prescribing guidelines, administered either under the tongue (sublingual) or between the gum and cheek (buccal)
Study NCT04995029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Buprenorphine
Description: Administered by subcutaneous injection
Study NCT06418113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection
Description: supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring
Study NCT06418113 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: resection
Description: supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring
Study NCT06418113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 4 weeks post-surgery, temozolomide (TMZ) will be administered for 6 months
Study NCT05067153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fragmin 5000 UNT in 0.2 ML Prefilled Syringe
Description: 30 days postoperative prophylactic treatment.
Study NCT05067153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fragmin 5000 UNT in 0.2 ML Prefilled Syringe
Description: 30 days postoperative prophylactic treatment.
Study NCT06418113 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiotherapy Stupp protocol
Description: radiotherapy + TMZ concurrently after 4 weeks of resection surgery, as per usual protocol: Three-dimensional radiotherapy planning to deliver a total dose of 60 Gy, with a fractionation of 2 Gy/day, 5 days/week, encompassing a 1-2 cm margin around the contrast-enhancing region defined on T1 imaging or the entire abnormal volume defined on T2 or FLAIR imaging (Li et al., 2016) + TMZ at 75 mg/m2/day for 7 days/week, for 6 weeks during radiotherapy.
Study NCT06418113 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy Stupp Protocol
Description: temozolomide (TMZ) will be administered for 6 months according to the Stupp protocol.
Study NCT05136053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG22515
Description: sterile solution for infusion
Study NCT05136053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile solution for infusion
Study NCT05136053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune System Activator
Description: sterile powder for injection
Study NCT05136053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Immune System Activator
Description: sterile powder for injection
Study NCT05351320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-0593 Tablets
Description: WX-0593 60 mg, tablets, orally, once daily for 7 days, followed by WX-0593 180 mg, tablets, orally, once daily
Study NCT05351320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Platinum-based chemotherapy
Study NCT05351320 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiation Therapy（TRT）
Description: Five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy
Study NCT04821297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive messages
Study NCT04821297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study NCT04821297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in an interview
Study NCT06519864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Azure Kinect-based Tandem Stance Test (ATST) and Physical Therapist's Measurements of Tandem Stance Test (PTST)
Description: For the Tandem Stance Test comparisons, the Azure Kinect-based Tandem Stance Test system quantified the distance traveled by the pelvic point to X, Y, and Z coordinates over a 30-second duration while the physical therapist measured the time elapsed until the participant lost balance was measured with a maximum of 30 seconds. Participants remained a tandem stance, positioning their preferred leg in front such that the heel of the front foot touched the toes of the back foot, ensuring both feet were aligned as straight as possible. They stood with holding on to two chairs each placed on their sides for stability and safety. Upon the cue to 'start', the participants let their hands go and both the Azure Kinect-based system and the physical therapist's stopwatch initiated their measurements. Participants tried to maintain their stance for 30 seconds. The participants had to reposition themselves when they stepped, used hands or lose balance for 30 seconds
Study NCT06519864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Azure Kinect-based Tandem Stance Test (ATST) and Physical Therapist's Measurements of Tandem Stance Test (PTST)
Description: For the Tandem Stance Test comparisons, the Azure Kinect-based Tandem Stance Test system quantified the distance traveled by the pelvic point to X, Y, and Z coordinates over a 30-second duration while the physical therapist measured the time elapsed until the participant lost balance was measured with a maximum of 30 seconds. Participants remained a tandem stance, positioning their preferred leg in front such that the heel of the front foot touched the toes of the back foot, ensuring both feet were aligned as straight as possible. They stood with holding on to two chairs each placed on their sides for stability and safety. Upon the cue to 'start', the participants let their hands go and both the Azure Kinect-based system and the physical therapist's stopwatch initiated their measurements. Participants tried to maintain their stance for 30 seconds. The participants had to reposition themselves when they stepped, used hands or lose balance for 30 seconds
Study NCT06519864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Azure Kinect-based Five Times Sit-to-Stand Test (AFTSS) and Physical Therapist's Measurements of Five Times Sit-to-Stand Test (PFTSS)
Description: The Five Times Sit-to-Stand Test (FTSS), standardized by Csuka and McCarty, has been designed to assessing lower limb strength as well as balance and postural control among elder population with high level of reliability. A previous study reported excellent intra-rater reliability (ICC=.914-.933) and inter-rater reliability (ICC=.988-.995) among healthy older adults. In addition, Five Times Sit-to-Stand Test more than 11.50 seconds had been reported to represent risk of falls among elders over 65-year-old. To assess Five Times Sit-to-Stand Test , a chair, 45cm in height and fixed to the ground, was placed three meters from the camera. Participants began seated, and on start cue, repeatedly stood up and sat down five times. The Azure Kinect-based system automatically ended its measurement as the participant completed the fifth stand, whereas the physical therapist manually measured time using the stopwatch. The time measures from the system and therapist were compared.
Study NCT06519864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Azure Kinect-based Five Times Sit-to-Stand Test (AFTSS) and Physical Therapist's Measurements of Five Times Sit-to-Stand Test (PFTSS)
Description: The Five Times Sit-to-Stand Test (FTSS), standardized by Csuka and McCarty, has been designed to assessing lower limb strength as well as balance and postural control among elder population with high level of reliability. A previous study reported excellent intra-rater reliability (ICC=.914-.933) and inter-rater reliability (ICC=.988-.995) among healthy older adults. In addition, Five Times Sit-to-Stand Test more than 11.50 seconds had been reported to represent risk of falls among elders over 65-year-old. To assess Five Times Sit-to-Stand Test , a chair, 45cm in height and fixed to the ground, was placed three meters from the camera. Participants began seated, and on start cue, repeatedly stood up and sat down five times. The Azure Kinect-based system automatically ended its measurement as the participant completed the fifth stand, whereas the physical therapist manually measured time using the stopwatch. The time measures from the system and therapist were compared.
Study NCT06519864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Azure Kinect-based Timed Up and Go Test (ATUG) and Physical Therapist's Measurements of Timed Up and Go Test (PTUG)
Description: The Timed Up and Go test (TUG) has been employed as a straightforward assessment of an individual's mobility, necessitating both static and dynamic balance. A Timed Up and Go test duration exceeding 9.50 seconds has been identified as indicative of a heightened fall risk in individuals aged 65 and older. A previous study reported excellent intra-rater reliability (ICC=.97) and inter-rater reliability (ICC=.96). Initiating in a seated position, participants stood upon commencement of the test. Simultaneously, the Azure Kinect-based system and stopwatch began the time measurements. Participants then walked a distance of three meters, turned around, retraced their steps, and resumed their seated position. The Azure Kinect-based system automatically terminated its timing once the participant was seated, while the physical therapist manually stopped the stopwatch. The time measures from the system and therapist were compared.
Study NCT06519864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Azure Kinect-based Timed Up and Go Test (ATUG) and Physical Therapist's Measurements of Timed Up and Go Test (PTUG)
Description: The Timed Up and Go test (TUG) has been employed as a straightforward assessment of an individual's mobility, necessitating both static and dynamic balance. A Timed Up and Go test duration exceeding 9.50 seconds has been identified as indicative of a heightened fall risk in individuals aged 65 and older. A previous study reported excellent intra-rater reliability (ICC=.97) and inter-rater reliability (ICC=.96). Initiating in a seated position, participants stood upon commencement of the test. Simultaneously, the Azure Kinect-based system and stopwatch began the time measurements. Participants then walked a distance of three meters, turned around, retraced their steps, and resumed their seated position. The Azure Kinect-based system automatically terminated its timing once the participant was seated, while the physical therapist manually stopped the stopwatch. The time measures from the system and therapist were compared.
Study NCT06519864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB)
Description: The assessment includes three tests: a Timed Up and Go test test where participants walked a distance of 3 meters at their comfortable pace; a Five Times Sit-to-Stand Test which the duration is also measured; and the standing balance test which determines a participant's capacity to maintain three different stances of side-by-side, semi-tandem, and full tandem, each for 10 seconds.